BICYCLE THERAPEUTICS PLC
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
BCYC$3.77+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · June 30, · · December 31, | ||||||
| · 2024 · 2023 | ||||||
| Assets · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $961,364 | | $526,423 | ||
| Accounts receivable | | 233 | | — | ||
| Prepaid expenses and other current assets | | 20,216 | | 11,406 | ||
| Research and development incentives receivable | | 46,443 | | 24,039 | ||
| Total current assets | | 1,028,256 | | 561,868 | ||
| Property and equipment, net | | 11,587 | | 14,515 | ||
| Operating lease right-of-use assets | | 10,933 | | 13,169 | ||
| Other assets | | 6,579 | | 5,792 | ||
| Total assets | | $1,057,355 | | $595,344 | ||
| Liabilities and shareholders’ equity | | | ||||
| Current liabilities: | | | | | ||
| Accounts payable | | $7,453 | | $13,050 | ||
| Accrued expenses and other current liabilities | | 28,135 | | 31,509 | ||
| Deferred revenue, current portion | | 11,619 | | 24,978 | ||
| Debt, current portion | | | 22,404 | | | — |
| Total current liabilities | | 69,611 | | 69,537 | ||
| Debt, net of discount and current portion | | | 8,505 | | | 30,698 |
| Operating lease liabilities, net of current portion | | 6,730 | | 9,382 | ||
| Deferred revenue, net of current portion | | | 93,994 | | | 110,216 |
| Other long‑term liabilities | | 4,702 | | 4,579 | ||
| Total liabilities | | 183,542 | | 224,412 | ||
| Commitments and contingencies (Note 11) | | | ||||
| Shareholders’ equity: | | | ||||
| Ordinary shares, including non-voting ordinary shares, £0.01 nominal value; 154,385,145 and 59,612,613 shares authorized on June 30, 2024 and December 31, 2023, respectively; 68,941,242 and 42,431,766 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | | 889 | | 550 | ||
| Additional paid-in capital | | 1,452,151 | | 883,446 | ||
| Accumulated other comprehensive loss | | (1,092) | | (1,304) | ||
| Accumulated deficit | | (578,135) | | (511,760) | ||
| Total shareholders’ equity | | 873,813 | | 370,932 | ||
| Total liabilities and shareholders’ equity | | $1,057,355 | | $595,344 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.